LAB21 Limited Appoints New CEO
Cambridge, 5th November … Lab21, a leading provider of healthcare and environmental diagnostic products and services has announced the appointment of Graham Mullis as its new CEO.
Graham has held executive positions at FTSE and Nasdaq listed medical device companies including 1-800 Contacts Inc and Biocompatibles International PLC and pharmaceutical roles at Hoechst Roussel Ltd and R P Scherer Ltd.
He has considerable experience in successfully launching new businesses and technologies in healthcare markets, with IPO and extensive M&A experience at a variety of medical and pharmaceutical companies.
Graham joins Lab21 from Optivue Ltd, a company formed to develop and license pharmaceutical & medical device applications in optical products, where he is a co-founder.
Commenting on Graham’s appointment, Nick Kerton, Chairman of Lab21, said: “We are extremely pleased to have someone of Graham’s calibre joining us. He has a proven track record as an entrepreneur and business leader in the healthcare field, and he will be an enormous asset as Lab21 continues to expand and develop its international reputation as a healthcare diagnostic provider.”
Graham has an MBA from Warwick Business School and BSc in Biochemistry with Physiology from Southampton University. Commenting on his new role, Graham added: “I am excited by the opportunity that exists for Lab 21 in both healthcare and environmental diagnostics. Lab21 really is at the cutting edge of diagnostic development and has experienced people that are committed to providing this rapidly expanding market with leading products and services. I look forward to steering Lab21 to further growth.”
About Lab21
Lab21 is a global provider of state-of-the-art diagnostic products and services, supporting drug discovery, healthcare and environmental monitoring. Its customers include healthcare providers, pharmaceutical and biotechnology companies, in addition to organisations that need to monitor their impact on the environment.
The Company has a growing test portfolio providing companion diagnostics and high technology assays for the growing integration of personalised medicine into healthcare. These services are specialised currently in infectious diseases, oncology and pharmacogenetics with emerging interests in cardiovascular and metabolic disease.
Lab21’s environmental monitoring business specialises in the detection of heavy metal contamination in soil and water. Its products provide information to help organisations take action to reduce pollution globally and to protect the water supply of millions of people globally.
Lab21’s clinical reference laboratory and corporate office is based in Cambridge and employs 48 people. The Company’s investors include Merlin Biosciences and Kreos Capital.
Website: www.lab21.com
Contacts at Lab21:
Media relations for Lab21: Northbank Communications
Tony Stephenson, Account Manager
Sue Charles, CEO
Claire Mosley, Account Executive
t : +44 (0) 20 7268 3002 e: lab21@northbankcommunications.com
At Lab21:
Graham Mullis, CEO t : +44 (0)1223 395450 e: graham.mullis@lab-21.com